{"id":21667,"date":"2024-07-02T05:54:54","date_gmt":"2024-07-02T05:54:54","guid":{"rendered":"https:\/\/clinlabint.com\/?p=21667"},"modified":"2024-07-02T12:42:37","modified_gmt":"2024-07-02T12:42:37","slug":"gyros-protein-technologies-launches-innovative-kit-for-detecting-anti-aav-antibodies","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/gyros-protein-technologies-launches-innovative-kit-for-detecting-anti-aav-antibodies\/","title":{"rendered":"Gyros Protein Technologies launches innovative kit for detecting anti-AAV antibodies"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Gyros Protein Technologies launches innovative kit for detecting anti-AAV antibodies<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Gyros Protein Technologies AB has introduced a new kit designed to streamline the detection of pre-existing antibodies against adeno-associated virus (AAV) vectors. The Gyrolab Generic Anti-Adeno Associated Virus (AAV) Kit aims to facilitate qualitative assessment of binding antibodies in both pre-clinical and clinical settings, supporting the development of AAV-based gene therapies.<\/strong><\/p>\n

<\/p>\n

Key features of the new kit<\/h4>\n

The ready-to-use kit is optimised for detecting total binding anti-capsid antibodies against commonly used AAV serotypes.
\nIt offers several advantages over existing methods:
\n\u2022 Eliminates the need for serotype-specific assay development
\n\u2022 Does not require capsid labelling, reducing variability
\n\u2022 Utilises small quantities of viral capsids, preserving drug volumes
\n\u2022 Compatible with all Gyrolab systems<\/p>\n

Streamlining the screening process<\/h4>\n

The kit\u2019s automation capabilities on Gyrolab systems offer significant benefits to clinical laboratory scientists:
\n\u2022 Reduced variability due to manual pipetting
\n\u2022 Accelerated workflows with results available within 90 minutes
\n\u2022 Decreased assay development time<\/p>\n

Expanding applications in gene therapy development<\/h4>\n

Mark Vossenaar, General Manager of the Biopharma\u00adceutical Development Division at Gyros Protein Technologies, commented on the kit\u2019s potential impact: \u201cThe new Gyrolab Generic Anti-AAV Kit is tailored to meet customer needs in the bioanalysis of AAV-based gene therapeutics, focusing on efficiency, resource, and time-savings.<\/p>\n

This innovative addition expands our portfolio of ready-to-use kits, providing a rapid, cost-effective solution for the detection of total binding antibodies without necessitating serotype-specific assay development or extensive optimization.\u201d<\/p>\n

Implications for gene therapy research<\/h4>\n

The introduction of this kit represents a significant advancement in the field of AAV-based gene therapies. By enabling more efficient screening for pre-existing immunity, researchers can:<\/p>\n

\u2022 Make more informed decisions regarding patient stratification
\n\u2022 Potentially improve the efficacy of gene therapy delivery
\n\u2022 Accelerate the development of novel gene therapies<\/p>\n

For more information, visit: https:\/\/www.gyrosproteintechnologies.com\/immunoassays\/products\/gyrolab-generic-anti-aav-kit<\/a><\/p>\n

Digital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n
\n